First two patients treated in pilot clinical study with bone biologics' nb1 bone graft device in spine fusion

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the company's nb1 bone graft device. nb1 is nell-1 protein combined with demineralized bone matrix (dbm) to provide rapid, specific and guided control over bone regeneration. this pilot cli.
BBLG Ratings Summary
BBLG Quant Ranking